Get the Stockscreener App
1.52
8.57%
0.12
After Hours:
1.56
0.04
+2.63%
Actuate Therapeutics Inc stock is traded at $1.52, with a volume of 109.48K.
It is up +8.57% in the last 24 hours and down -19.15% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$1.40
Open:
$1.37
24h Volume:
109.48K
Relative Volume:
0.62
Market Cap:
$36.37M
Revenue:
-
Net Income/Loss:
$-21.54M
P/E Ratio:
-1.5347
EPS:
-0.9904
Net Cash Flow:
$-19.60M
1W Performance:
-0.65%
1M Performance:
-19.15%
6M Performance:
-76.58%
1Y Performance:
-74.71%
1-Day Range:
$1.37
$1.54
1-Week Range:
$1.37
$1.58
52-Week Range:
$1.37
$9.22
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
1.52 | 33.50M | 0 | -21.54M | -19.60M | -0.9904 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Dynamic Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Price to book forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Price to sales forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Price to earnings forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Actuate Therapeutics (ACTU) Declines Sharply – Key Support Tested at $1.73Double Top - dars.gov.et
Actuate Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACTU) - TradingView
ACTU Forecast — Price Target — Prediction for 2027 - TradingView
Actuate Therapeutics Inc (ACTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actuate Therapeutics Inc (ACTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actuate Therapeutics Inc (ACTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Institutional Confidence - TradingKey
Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actuate Therapeutics Inc (ACTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACTU Q1 2026 Earnings: Wider-than-Expected Loss Despite Positive Stock ReactionFinancial Health Score - newsline.com
Actuate Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
ACTU Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Advances PipelineEarnings Volatility Report - newsline.com
Buy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained - TipRanks
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion - Investing.com
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Actuate’s elraglusib to be evaluated in BEACON2 neuroblastoma trial - Investing.com
Actuate’s elraglusib to be evaluated in BEACON2 neuroblastoma trial By Investing.com - Investing.com South Africa
Actuate Therapeutics to Evaluate Elraglusib in BEACON2 Clinical Trial for Relapsed Neuroblastoma in Partnership with Cancer Research UK Clinical Trials Unit - Quiver Quantitative
Experimental cancer drug elraglusib joins landmark pediatric neuroblastoma trial - Stock Titan
Actuate Therapeutics (ACTU) Surges 6.59% as Biotech Momentum Builds Above Key SupportSystematic Flow - newsline.com
Elraglusib shows significant survival benefits in metastatic pancreatic cancer combined with standard chemo. - Pluang
Actuate presents elraglusib trial data at ASCO meeting By Investing.com - Investing.com South Africa
Actuate presents elraglusib trial data at ASCO meeting - Investing.com
Actuate Therapeutics Reports Positive Survival Outcomes for Elraglusib in Combination with Standard Chemotherapies for Metastatic Pancreatic Ductal Adenocarcinoma at ASCO 2026 - Quiver Quantitative
Actuate Therapeutics Announces ASCO Poster Presentations - GlobeNewswire
Actuate Therapeutics, Inc. Presents Clinical And Biomarker Data For Elraglusib In First-Line Metastatic Pancreatic Cancer At ASCO - marketscreener.com
Actuate Therapeutics (ACTU) Declines 2.88% as Stock Nears Key Support ZoneEarnings Beat Stocks - The Legal Advocate
Actuate Therapeutics (ACTU) Holds Near Support Amid Low VolatilityVolume Spike Alerts - The Legal Advocate
Actuate Therapeutics (ACTU) Drops 4.09% as Shares Test Critical $2.00 Support LevelFlat Correction - newsline.com
ACTUActuate Therapeutics Inc Stock Price and Quote - Finviz
ACTU Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseGuidance vs Actual - Newser
Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com India
Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing - Minichart
Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor - TipRanks
Actuate Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com
Actuate Therapeutics, Inc.Common stock (NQ: ACTU - The Chronicle-Journal
Actuate Therapeutics (ACTU) Holds Near Support After Modest UptickCrowd Breakout Signals - Newser
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
Actuate Therapeutics Inc Stock (ACTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):